Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRXBiotechnology
-$0.01 today
- Market cap
- $3.85B
- Beta
- 0.74
- P/E (TTM)
- 17.3
- EPS (TTM)
- $1.81
Volume 0.00M
Average 2.17M
CPRX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Catalyst Pharmaceuticals, Inc.NASDAQ: CPRX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $49.32M rose 5.1% year over year, behind the +10.4% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 7.7% from the prior quarter. Over 3 fiscal years it compounded at +50.3% a year.
Context
- Selling, general & admin amounted to 32.9% of revenue in FY2025, down 3.3 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 2 analysts of $208.97M (+7.9%) for the fiscal year ending Dec 2026, a slowdown from the +9.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $49.32M-7.7% QoQ
- Last fiscal yearDec 2025
- $193.75M+9.0% YoY
- LTMMar 2026
- $196.16M+10.4% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 193.75M USD
- Year-over-year change
- +9.0%
- 4-year CAGR
- +40.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 193.75M | +9.0% |
| FY2024 | 2024-12-31 | 177.74M | +32.9% |
| FY2023 | 2023-12-31 | 133.71M | +134.2% |
| FY2022 | 2022-12-31 | 57.09M | +15.0% |
| FY2021 | 2021-12-31 | 49.63M | — |
Selling, General & Admin vs competitors
How CPRX compares with its peers on the latest reported figures
- CPRX's LTM Mar 2026 selling, general & admin of $196.16M is the 3rd highest of the 9 companies compared; the peer median is $165.89M.
- Its year-over-year change of +10.4% is the 8th highest of 9, against a peer median of +22.1%.
- Selling, general & admin amounts to 32.9% of revenue for CPRX, versus a peer median of 80.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $230.9M | +30.2% | +26.1% | 27.5% | |
| LTM Sep 2026 | $198.39M | +32.1% | +60.5% | 34804.4% | |
| LTM Mar 2026 | $196.16M | +10.4% | +50.3% | 32.9% | |
| LTM Mar 2026 | $187.06M | +11.8% | +14.0% | 283.2% | |
| LTM Jun 2026 | $180.38M | +13.3% | -3.2% | 58.5% | |
| LTM Jun 2026 | $151.41M | -30.0% | +29.3% | 276.0% | |
| LTM Jun 2026 | $125.4M | +14.0% | +9.0% | 80.4% | |
| LTM Jun 2026 | $69.2M | +144.0% | +94.7% | — | |
| LTM Mar 2026 | $69.19M | +65.4% | +42.7% | 30.7% | |
| Peer median (excluding CPRX) | $165.89M | +22.1% | +27.7% | 80.4% | |
Competitors are the stored peer set for CPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 140.83M | 214.2M | 398.2M | 491.73M | 588.99M |
| Cost of Revenue | 21.88M | 34.39M | 51.97M | 68.85M | 87.25M |
| Gross Profit | 118.95M | 179.81M | 346.24M | 422.89M | 501.74M |
| Gross Margin | 84.5% | 83.9% | 86.9% | 86.0% | 85.2% |
| Research & Development | 16.94M | 19.79M | 93.15M | 12.65M | 12.71M |
| Selling, General & Admin | 49.63M | 57.09M | 133.71M | 177.74M | 193.75M |
| Operating Expenses | 66.56M | 77.97M | 259.43M | 227.77M | 243.96M |
| Depreciation & Amortization | 192K | 1.24M | 32.88M | 37.77M | 37.87M |
| EBITDA | 52.86M | 105.96M | 127.39M | 254.04M | 321.39M |
| EBITDA Margin | 37.5% | 49.5% | 32.0% | 51.7% | 54.6% |
| Operating Income | 52.39M | 101.84M | 86.81M | 195.12M | 257.78M |
| Operating Margin | 37.2% | 47.5% | 21.8% | 39.7% | 43.8% |
| Interest Income | 0 | 0 | 0 | 16.06M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 282K | 2.88M | 7.7M | 21.14M | 25.74M |
| Income Before Tax | 52.67M | 104.72M | 94.51M | 216.26M | 283.52M |
| Pre-Tax Margin | 37.4% | 48.9% | 23.7% | 44.0% | 48.1% |
| Income Tax Expense | 13.19M | 21.64M | 23.1M | 52.37M | 69.19M |
| Net Income | 39.48M | 83.08M | 71.41M | 163.89M | 214.33M |
| Net Margin | 28.0% | 38.8% | 17.9% | 33.3% | 36.4% |
| EPS (Basic) | 0.38 | 0.80 | 0.67 | 1.38 | 1.75 |
| EPS (Diluted) | 0.37 | 0.75 | 0.63 | 1.31 | 1.68 |
| Weighted Avg Shares | 103.38M | 103.37M | 106.28M | 118.46M | 122.29M |
| Weighted Avg Shares (Diluted) | 107.8M | 111.38M | 113.75M | 124.94M | 127.26M |
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
Intrinsic Alpha fair value
Locked
Current Price
$31.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.